This course has expired. You can still review the content but course credit is no longer available.
This course is designed to educate ophthalmologists on the fundamentals of optimizing outcomes in presbyopia-correcting IOL patients. In this course, faculty will discuss how materials and other IOL parameters elevate quality of vision. Faculty will also review recommendations for minimizing postoperative refractive errors to maximize patient satisfaction.
Supported by unrestricted education grants from Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC, and The Fundingsland Group. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Evolve Medical Education, LLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Douglas D. Koch, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:Alcon, Carl Zeiss Meditec, Johnson & Johnson Vision, and Perfect Lens. Stock/Shareholder: Ivantis, and Vivior.
Daniel H. Chang, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, Mynosys, and Omega Ophthalmics. Grant/Research Support: Acufocus, Johnson & Johnson Vision, and Mynosys. Stock/Shareholder: Omega Ophthalmics.
Cathleen McCabe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompe, Eye Point Pharma, Ivantis, Novartis, Ocular Therapeutix, Omeros, and Sight Sciences. Grant/Research Support: Alcon Vision, Allergan, Dompe, Eye Point Pharma, Glaukos, Ivantis, Johnson & Johnson Vision, Novartis, and Ocular Therapeutix.
The Evolve Medical Education and The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.